Caliway Biopharmaceuticals Co (ROCO:6919) ROCE % : -22.20% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Caliway Biopharmaceuticals Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Caliway Biopharmaceuticals Co's annualized ROCE % for the quarter that ended in Jun. 2024 was -22.20%.

Caliway Biopharmaceuticals Co ROCE % Historical Data

The historical data trend for Caliway Biopharmaceuticals Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caliway Biopharmaceuticals Co ROCE % Chart

Caliway Biopharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-197.03

-84.38

-52.97

-30.73

-19.77

Caliway Biopharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial				-23.50	-26.64	-49.33	-19.39	-22.20

Caliway Biopharmaceuticals Co ROCE % Calculation

Caliway Biopharmaceuticals Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-487.957	/	( ( (1233.081 - 48.363)	+	(3826.503 - 73.679) )	/ 2 )
	=	-487.957	/	( (1184.718	+	3752.824)	/ 2 )
	=	-487.957	/	2468.771
	=	-19.77 %

Caliway Biopharmaceuticals Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-789.87	/	( ( (3826.503 - 73.679)	+	(3443.778 - 80.352) )	/ 2 )
	=	-789.87	/	( ( 3752.824	+	3363.426 )	/ 2 )
	=	-789.87	/	3558.125
	=	-22.20 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Caliway Biopharmaceuticals Co (ROCO:6919) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Caliway Biopharmaceuticals Co ROCE % Related Terms

Thank you for viewing the detailed overview of Caliway Biopharmaceuticals Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Caliway Biopharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caliway Biopharmaceuticals Co Ltd (ROCO:6919) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.99, Sec. 1, Xintai 5th Road, 32F.-9, Xizhi District, New Taipei City, TWN, 221

Website

https://www.caliway.com.tw

Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its leading candidate, CBL-514, is a new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects.

Caliway Biopharmaceuticals Co Headlines

No Headlines